Morning Market Brief: AI Pause, Fed Signals, Biotech

Good morning. Grab your coffee—here’s what you need to know before the bell.

Enhanced Market Commentary

While everyone’s fixated on AI’s next spending spree, few are sizing up the timing mismatch: big tech’s infrastructure build-out may hit a lull in 2026 just as SMBs log real demand. That pause will expose companies loading up on GPUs at peak prices—and that’s a capital efficiency risk no one in Silicon Beach wants to admit.

Connect the dots between Aeluma’s laser-focus on milestones and the global auto industry’s plea for cooperation: both stories are about execution over hype. If biotech can deliver gene-editing breakthroughs on schedule and the auto sector can free trade without political sabre-rattling, investors stand to see real returns rather than headline-grabbing promises.

Actionable takeaway: screen your portfolio for companies built on operational discipline—those hitting targets without flashy theatrics. When the market whipsaws, stocks with tangible progress will emerge as the only safe harbour.